Heart allograft rejection: molecular diagnosis using intra-graft targeted gene expression profiling
- 4 December 2025
- journal article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (8) , 956-970
Abstract
Background and Aims: Tissular gene expression profiling applicable to formalin-fixed, paraffin-embedded (FFPE) endomyocardial biopsies (EMBs) may refine the diagnosis of cardiac rejection while being easily implemented in clinical practice. This study aimed to develop and validate the first FFPE-based molecular diagnostic system dedicated to heart transplant rejection. Methods: An international study was conducted (NCT06436027), establishing a deeply phenotyped cohort of heart transplant recipients. EMBs were graded according to international classifications, and gene expression was analysed on FFPE-EMBs using the Banff Human Organ Transplant Panel. Molecular classifiers for antibody-mediated rejection (AMR) and acute cellular rejection (ACR) were developed, with discrimination and calibration assessed in internal and external validation cohorts. Results: A total of 671 biopsies were included, with 591 in the main cohort (AMR: n = 188, ACR: n = 289, matched non-rejection: n = 114); this was split into a derivation set (n = 475) and an internal validation set (n = 116). The external validation cohort comprised 80 biopsies (AMR: n = 20, ACR: n = 32, non-rejection: n = 28). AMR was associated with significant transcripts related to the interferon-gamma pathway, endothelial activation, and monocyte-macrophage recruitment, while ACR was characterized by transcripts related to T-cell receptor signalling, CD3 receptor activation, and CD28 signalling. Molecular ACR and AMR models accurately identified rejection in the validation cohorts (internal: ROC-AUC: AMR = 0.812, ACR = 0.849; external: ROC-AUC: AMR = 0.822, ACR = 0.815) and were strongly associated with pathologic severity. Calibration was adequate. An automated report was developed to enhance the clinical applicability of these classifiers. Conclusions: A novel FFPE-based molecular diagnostic system accurately identified cardiac allograft rejection. This tool is readily applicable in clinical practice as a companion to pathology and has the potential to refine the diagnosis of rejection.Keywords
Funding Information
- OrganX
This publication has 42 references indexed in Scilit:
- Report of the 2022 Banff Heart Concurrent: Focus on non-human leukocyte antigen antibodies in rejection and the pathology of “mixed” rejectionAmerican Journal of Transplantation, 2023
- The evolving use of biomarkers in heart transplantation: Consensus of an expert panelAmerican Journal of Transplantation, 2023
- Overfitting and Optimism in Prediction Models2019
- Minimum sample size for developing a multivariable prediction model: PART II ‐ binary and time‐to‐event outcomesStatistics in Medicine, 2018
- The management of antibodies in heart transplantation: An ISHLT consensus documentThe Journal of Heart and Lung Transplantation, 2018
- Building a tissue-based molecular diagnostic system in heart transplant rejection: The heart Molecular Microscope Diagnostic (MMDx) SystemThe Journal of Heart and Lung Transplantation, 2017
- The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence AnalysesCurrent Protocols in Bioinformatics, 2016
- Late antibody-mediated rejection after heart transplantation: Mortality, graft function, and fulminant cardiac allograft vasculopathyThe Journal of Heart and Lung Transplantation, 2015
- The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantationThe Journal of Heart and Lung Transplantation, 2013
- Revision of the 1990 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Heart RejectionThe Journal of Heart and Lung Transplantation, 2005